Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05944250 · ClinicalTrials.gov registry record · NA
A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT05944250: Completed NA study, sponsored by Stanford University.
NCT05944250 is a NA study that has completed, run by Stanford University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05944250, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a subtype of epidermolysis bullosa (EB), an inherited skin condition that presents with blistering skin. The Spincare device, developed by Nanomedic, is the first portable tool that delivers a non-invasive, non-therapeutic electrospun, nanofibrous matrix dressing to wounds to promote healing. The aim of this study is to determine the suitability of this device in RDEB wounds and assess its wound healing properties, safety and tolerability.
Interventions
- DEVICE Spincare matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2024-08-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05944250
The ClinicalTrials.gov registry entry for NCT05944250 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spincare matrix is the first listed.
NCT05944250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05944250 about?
NCT05944250 is a clinical study titled "A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients". Recessive dystrophic epidermolysis bullosa (RDEB) is a subtype of epidermolysis bullosa (EB), an inherited skin condition that presents with blistering skin. The Spincare device, developed by Nanomedic, is the first portable tool that delivers a non-invasive, non-therapeutic electrospun, nanofibrous...
What is the current status of trial NCT05944250?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2023-09-19. Estimated completion is 2024-08-14.
What interventions are being tested in trial NCT05944250?
The interventions under investigation include: Spincare matrix (DEVICE).
Who is sponsoring clinical trial NCT05944250?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.